Schraffordt Koops H, Eggermont A M, Liénard D, Kroon B B, Hoekstra H J, Van Geel A N, Nieweg O E, Lejeune F J
Department of Surgical Oncology, Groningen University Hospital, The Netherlands.
Semin Surg Oncol. 1998 Apr-May;14(3):210-4. doi: 10.1002/(sici)1098-2388(199804/05)14:3<210::aid-ssu4>3.0.co;2-b.
Hyperthermic isolated limb perfusion (HILP) with various chemotherapeutic agents has been used for the local treatment of high-grade soft tissue sarcomas (STS) of the extremities, but in most cases, with a disappointing result. Most such regimens certainly should not be considered superior to surgery plus radiotherapy. Although the majority of extremity STS can be resected locally, some are very large and are in close proximity to bone, nerve or blood vessels. In these cases, amputation is the only means of resecting the tumour. A new combination of drugs used in the set-up of HILP with tumour necrosis factor-alpha and melphalan has emerged as a very promising option for the limb-saving management of locally advanced STS. In recent studies, complete response rates of approximately 30% and partial remission rates of 50% have been achieved, while the overall limb-salvage rate is more than 80%.
采用多种化疗药物进行的热灌注隔离肢体疗法（HILP）已用于肢体高级别软组织肉瘤（STS）的局部治疗，但在大多数情况下，效果令人失望。大多数此类治疗方案肯定不应被视为优于手术加放疗。尽管大多数肢体STS可以进行局部切除，但有些肿瘤非常大，且与骨骼、神经或血管相邻。在这些情况下，截肢是切除肿瘤的唯一方法。一种用于HILP治疗的新药物组合，即肿瘤坏死因子-α与美法仑，已成为局部晚期STS保肢治疗中一个非常有前景的选择。在最近的研究中，完全缓解率约为30%，部分缓解率为50%，而总体保肢率超过80%。
